MELINTA THERAPEUTICS, LLC

REZZAYO

Manufacturer:

MELINTA THERAPEUTICS, LLC

Rezzayo HCPCS:

J0349

HCPCS Code Descriptor:

Injection, rezafungin, 1 mg

Category:

J Code

Rezzayo NDCs:

70842-0240-01

Primary Type:

Anti-Fungal

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Rezzayo:

REZZAYO is an Anti-Fungal drug manufactured by Melinta and administered via the intravenous route of administration. The J Code: J0349 is aligned to the drug REZZAYO.

REZZAYO is an antifungal medication commonly indicated for use in patients who have very few or no other treatment options available for invasive candidiasis or candidemia. It is an echinocandin that effectively inhibits the 1,3-ꞵ-D-glucan synthase enzyme, preventing further formation of 1,3-ꞵ-D-glucan, a vital component in the cell walls of fungi. This mechanism of action has a fungicidal effect on Candida. REZZAYO (J0349) is indicated for use in adults over the age of 18. Patient assistance for this medication is available through Rezzayo.

ACCESS PRICING AND MORE BY REGISTERING

J0349 Added Date:

October 1, 2023

J0349 Effective Date:

October 1, 2023

J0349 Termination Date:

HCPCS Active

Rezzayo billing and coding information can be found through Melinta Therapeutics, Llc at the link below:
Rezzayo patient assistance information can be found through Melinta Therapeutics at the URL: https://www.rezzayo.com/support-and-resources/
REZZAYO prescribing information can be found at the link below:
Information regarding REZZAYO’s side effects can be found at MedlinePlus